David G. Alleva

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

Ludwig Kappos, Giancarlo Comi, Hillel Panitch et al. · Nature Medicine · 2000 · 514 citations

Life Sciences, Immunology, Neurology +17

Tumor-induced regulation of suppressor macrophage nitric oxide and TNF- <i>alpha</i> production. Role of tumor-derived IL-10, TGF- <i>beta</i> , and prostaglandin E2.

David G. Alleva, Carol J. Burger, K D Elgert · The Journal of Immunology · 1994 · 243 citations

Life Sciences, Immunology, Oncology +17

A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin

David G. Alleva, Paul D. Crowe, Liping Jin et al. · Journal of Clinical Investigation · 2001 · 210 citations · Full text

Life Sciences, Endocrinology, Immunology +16

Immunological Characterization and Therapeutic Activity of an Altered-Peptide Ligand, NBI-6024, Based on the Immunodominant Type 1 Diabetes Autoantigen Insulin B-Chain (9–23) Peptide

David G. Alleva, Amitabh Gaur, Liping Jin et al. · Diabetes · 2002 · 128 citations · Full text

Life Sciences, Endocrinology, Immunology +17

Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice.

David G. Alleva, R Pavlovich, Cameron Grant et al. · Diabetes · 2000 · 121 citations · Full text

Life Sciences, Immunology, Pathology +17